Topic outline

  • General

    Collapse all Expand all
    After completing this course, you will be able to:
    • Describe the process of medicine discovery and development and identify the critical factors and decision points
    • Explain the concepts of efficacy and safety of a medicine
    • Relate pharmacovigilance to the concept of benefit - risk of medicine
    • Understand the concepts of life-cycle and intellectual property management of a medicine
     

    EUPATI Open Classroom content is free for all learners.
    At the end of each course you can test your knowledge and earn a certificate for a 10-euro administrative fee. If interested, click the button below:

    Enrol & Access the assessment

    Welcome to the lesson 'Process of Medicines Discovery and Development'! Throughout your learning, you will learn about the 12 steps of medicines R&D as well as the basics of the process. The lesson should take up to 2 hours (average). Please note that this lesson is very important as it sets the basis for the upcoming and other courses of this Programme.

  • Introduction

    It takes over 12 years and on average costs over €1 billion to do all the research and development necessary before a new medicine is available for patients to use. Medicines development is a high risk venture. The majority of substances (around 98%) being developed do not make it to the market as new medicines. This is mostly because when you look at the benefits and risks (negative side effects) found during development, they do not compare well with medicines that are already available to patients.

    The steps involved in developing a new medicine are described below.

    Design by EUPATI

  • Steps of the Medicines Development Process

  • Concepts of 'Efficacy' and 'Safety'

    The concept of efficacy and safety of a medicine refers to the ability of a treatment to work while causing no unnecessary harm.

    • This means that the benefit of taking a medicine, despite potential side effects, is higher than the risk of leaving the condition untreated.
    • To phrase it differently a medicine is beneficial when it produces the desired effect (efficacy) with a suitably low chance of side effects (safety).

    This is also known as the ‘benefit-risk relationship’ (or benefit-risk ratio, it was previously known as the risk-benefit ratio/relationship).


  • Pharmacovigilance

    After a medicine becomes available to patients, the efficacy and safety still need to be monitored. This is called ‘pharmacovigilance’. This is typically co-ordinated by the pharmacovigilance department of the pharmaceutical company along with the Regulatory Authorities, healthcare professionals and patients. The World Health Organisation (WHO) defines pharmacovigilance as ‘[…] the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem’ [1].

    The concept of pharmacovigilance was introduced in the late 1960's, after the thalidomide disaster. Close to 10.000 babies were born with problems or ‘deformities’ caused by thalidomide taken by their mothers during pregnancy. At that time, thalidomide was sold mainly as a sedative, but it was also used for the treatment of morning sickness in pregnant women. It had never been tested for this indication (condition) since at that time (1957) no clinical trials in humans were required.

    Based on this disaster, the concept of pharmacovigilance was put into action.

    Today, before a medicine is made available to patients, it has typically been tested (depending on the disease) on a population of at least 5.000 persons. This corresponds to about 0.00007% of the world’s population [2]. The testing period for the medicine is based on a limited time period. This is why the long-term efficacy and safety of the medicine must be monitored and continuously evaluated while on the market, or, in other words, under ‘real-life’ conditions. If a patient gets any side effects, it is recommended that they talk to a doctor, pharmacist or nurse. This includes any possible side effects listed or not listed in the package leaflet. In many EU member states, side effects can be reported directly via the national reporting system available on the websites of the national competent authority (NCA). By reporting side effects more information will become available on the safety of a medicine.

  • Intellectual Property and Life-Cycle Considerations

  • Assessment

    • Assessment Quiz
      Learners must
      Receive a grade
      Receive a passing grade

      To receive a certificate for this course, you must be enrolled in the course (click on 'Enrol me in this course' yellow button at the top right on the course page), then complete the assessment and obtain at least 70% of correct answers. You have 10 attempts in total. Good luck! 

  • References

    1. The importance of pharmacovigilance. Safety monitoring of medicinal products by World Health Organization, 2002. Available at:  https://www.who.int/publications/i/item/10665-42493
    2. Pharmacovigilance: ensuring the safe use of medicines by World Health Organization, 2004. Available at: https://www.who.int/publications/i/item/WHOEDM2004.8